Quince Therapeutics, Inc. (QNCX): EPS (Basic)
-$1.68
Year ended 2025-12-31
| Period ended | EPS (Basic) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$1.68 | n/m | 2026-04-10, From 2025-01-01 |
| 2024-12-31 | -$1.31 | n/m | 2026-04-10, From 2024-01-01 |
| 2023-12-31 | -$0.84 | n/m | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | -$1.54 | n/m | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$3.03 | n/a | 2023-03-15, From 2021-01-01 |
EPS (Basic) at similar companies
| Company | Year ended | EPS (Basic) | Change YoY |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | 2025-12-31 | -$1.68 | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | -$0.80 | n/m |
| LeonaBio, Inc. (LONA) | 2025-12-31 | -$24.70 | n/m |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$32.37 | n/m |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | -$2.45 | n/m |
| Anavex Life Sciences Corp. (AVXL) | 2025-09-30 | -$0.54 | n/m |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | -$0.08 | n/m |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | -$1.17 | n/m |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$0.28 | n/m |
Compare QNCX, ATYR, LONA, SRZN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗